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Abstract 18
Ebolaviruses are non-segmented, negative-sense RNA viruses (NNSVs) within the order 19
Mononegavirales that possess the multifunctional virion protein 35 (VP35), a major determinant 20 of virulence and pathogenesis that is indispensable for viral replication and host innate immune 21 evasion. VP35 is functionally equivalent to the phosphoprotein (P) of other mononegaviruses 22 such as rhabdoviruses and paramyxoviruses. Phosphorylation of the P protein is universally 23 regarded as functionally important however, a regulatory role(s) of phosphorylation on VP35 24 function remains unexplored. Here, we identified a highly conserved Ser129 residue near the 25 homo-oligomerization coiled coil motif, which is essential for VP35 functions. Affinity-purification 26
MS followed by post-translational modification (PTM) analysis predicted phosphorylation of 27
Ser129. Co-immunoprecipitation, cross-linking, and biochemical characterization studies 28 revealed a moderately decreased capacity of VP35-S129A to oligomerize. Functional analysis 29
showed that Ser-to-Ala substitution of Ebola virus (EBOV) VP35 did not affect IFN inhibitory 30 activity but nearly abolished EBOV minigenome activity. Further coimmunoprecipitation studies 31 demonstrated a lost interaction between VP35-S129A and the amino terminus of the viral 32 polymerase but not between viral nucleoprotein (NP) or VP35-WT. Taken together, our findings 33 provide evidence that phosphorylation modulates VP35 function, supporting VP35 as a NNSV P 34
protein and providing a potentially valuable therapeutic target. Ebolaviruses are zoonotic pathogens associated with severe hemorrhagic disease in humans 55 (Messaoudi et al., 2015 , Nelson et al., 2017 . The genus Ebolavirus, which is of the family 56
Filoviridae and order Mononegavirales, includes six species of filamentous, enveloped, non-57
segmented negative-sense RNA viruses (NNSVs): Ebola (EBOV), Sudan (SUDV), Reston 58
(RESTV), Tai Forest (TAFV), Bundibugyo (BDBV), and Bombali (BOMV) viruses (Feldmann et 59 al., 2013, Kuhn, 2017 , Goldstein et al., 2018 . Among these, EBOV has caused the most 60 substantial outbreaks, along with SUDV and BDBV (Messaoudi et al., 2015) . Once sporadic, 61
EBOV outbreaks have become increasingly frequent and large, as evidenced by the intermediates, inhibiting PACT-induced RIG-I ATPase activity, preventing kinases TANK-binding 77 kinase 1 (TBK1), and/or IB kinase epsilon (IKKε) from activating interferon regulatory factors 3 78 and 7 (IRF3/IRF7), inactivating IRF7 by SUMOylation, and inhibiting TRIM6-mediated type I IFN 79
production ( In this study, we aimed to further elucidate modulation of VP35 function by evaluating it as a 122 NNSV P protein. We used affinity purification-mass spectrometry (AP-MS) to identify putative 123 post-translational modifications (PTMs) of VP35. Phosphorylation was predicted for a highly 124
conserved Ser129 residue proximal to the homo-oligomerization domain. Oligomerization 125 studies indicated that an alanine mutant VP35-S129A had moderately reduced ability to homo-126
oligomerize. Further functional studies revealed that while the mutant retained IFN antagonist 127 activity, minigenome activity was nearly abolished. VP35-NP and VP35-L interactions were 128 interrogated by co-immunoprecipitation (co-IP) and immunofluorescence (IF) experiments. 129
While VP35-NP interaction remained intact, VP35-L was abrogated, indicating that 130 phosphorylation of VP35 at S129 is crucial to the ability of VP35 to interact with L. These 131 results support VP35 as a NNSV P protein and further elucidate the regulation of VP35 132 functions, potentially offering a novel pan-filovirus therapeutic target. 133
Methods 134
Antibodies 135
Mouse anti-HA (H3663), rabbit anti-HA (H6908), mouse anti-FLAG (F3165), rabbit anti-FLAG 136 (F7425), rabbit anti-ISG56 (SAB1410690), and mouse anti-Calnexin (C7617) antisera were 137 purchased from Sigma-Aldrich (ST. Louis, MO, USA). Rabbit anti-VP35 (GTX134032) was 138 purchased from GeneTex (Irvine, CA, USA). Mouse anti-His (TA150088) was purchased from 139
OriGene (Rockville, MD, USA). Rabbit anti-L was purchased from IBT BioServices (Rockville, 140 MD, USA).Goat anti-rabbit HRP (65-6120), goat anti-mouse HRP (32430), goat anti-mouse 141
Alexa Fluor 488 (A32723), goat anti-rabbit Alexa Fluor 568 (A11011), and Hoechst 33342 142 (H3570) were purchased from ThermoFisher Scientific (Grand Island, NY, USA). 143
Cell lines and viral RNA production 144
HeLa, HEK293T, and A549 cells were grown in Dulbecco's modified Eagle's medium (Gibco) 145
supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Sigma). 146
Cells were maintained at 37°C in a humidified 5% CO 2 incubator. Viral RNA (vRNA) was 147 produced in A549 cells, infected with IAV/Puerto-Rico/8/34 (IAV PR8) strain at a multiplicity of 148 infection of 5. Five hours after infection, total RNA was isolated using the RNeasy® Kit from 149
Qiagen (Hilden, Germany). TRIzol™ Reagent was purchased from Thermo Fisher Scientific. 150
Plasmids and Reagents 151
Plasmid pGL-IFN-β-luc was kindly provided by Professor Stephan Ludwig, Institute of Molecular 152
Virology, University of Münster, Germany). pRL-TK was purchased form Promega (Promega 153 Italia S.r.l. Milan, Italy). pcDNA3-EBOV VP35, carrying EBOV VP35 gene form Zaire species 154
(1976 Yambuku-Mayinga strain) was constructed as previously reported (Cannas et al., 2015) . 155
The VP35-S129A substitution was introduced in the pcDNA3-EBOV VP35 plasmid using the 156
QuikChange mutagenesis kit by following the manufacturer's instructions (Agilent Technologies  157 Inc., Santa Clara, CA). Primers' sequences: VP35-S129A Forward:5'-158 GATATGGCAAAAACAATCGCCTCATTGAACAGGGTTTG-3'; VP35-S129A reverse: 5'-159
CAAACCCTGTTCAATGAGGCGATTGTTTTTGCCATATC-3'. pCAGGS-HA-EBOV-NP was 160 purchased from BEI (NR-49343). pCAGGS-NP-V5, pCAGGS-V5-VP30, and pcDNA3 vectors 161
were generated at the USAMRIID. 
Mass spectrometry analysis 185
Affinity-tagged VP35 was overexpressed in HeLa cells using Lipofectamine 2000 as per 186
manufacturer's instruction. Affinity purified material was resolved by SDS-PAGE and stained 187
with Coomassie (ThermoFisher Scientific). The stained protein band corresponding to protein of 188
interest was excised and processed for in-gel digestion at the UNMC proteomics facility using 189 the protocol of Shevchenko and colleagues (Shevchenko et al., 2006) . Extracted peptides were tryptic peptides with a maximum of two missed cleavage sites. Acetylation of protein N-terminus 206
and oxidized methionine were included as variable modifications and carbamidomethylation of 207 cysteine was set as fixed modification. The precursor mass tolerance threshold was set 10 ppm 208
for and maximum fragment mass error was 0.02 Da. Qualitative analysis was performed using 209 PEAKS 8.5 software. The significance threshold of the ion score was calculated based on a 210 false discovery rate of ≤ 1%. 211
Co-immunoprecipitations (co-IPs) 212
HeLa cells (1 × 10 6 cells) were transfected with the indicated plasmids using 3 µL of the 213 transfection reagent jetPRIME (Polyplus) per 1 µg DNA per manufacturer's instructions. The 214
total amount of DNA for each transfection was kept constant in each experiment by 215 complementing with empty vector. Twenty-four h post-transfection, cells were lysed in a 216 modified RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% NP-40, 0.25% 217 Na-deoxycholate) containing protease and a phosphatase inhibitor cocktail (Thermo Scientific, 218
Waltham, MA, USA). Approximately 10% WCL was reserved for IB analysis before performing 219 co-IPs. To immunoprecipitate indicated proteins, lysates were incubated with EZview Red ANTI-220 FLAG M2 Affinity Gel (Sigma) or EZview Red Anti-HA Affinity Gel (Sigma) for 1 h at 4 °C. Beads 221
were washed 4 to 5 times with TBS, re-suspended in 2X Lane Marker Reducing Sample Buffer 222 (Thermo Scientific), and then subjected to SDS-PAGE and immunoblotting, as indicated below. 223
Immunoblotting (IB) 224
Cell lysates were subjected to reducing SDS-PAGE and proteins were transferred onto PVDF 225 membranes. Blots were probed with indicated primary antibodies either 1-2 h at RT or overnight 226 at 4°C. Secondary incubations were performed for 1-2 h at RT using either goat anti-rabbit HRP 227
or goat anti-mouse HRP. Radiance chemiluminescence substrate (Azure Biosystems; Dublin, 228 CA, USA) was used to visualize protein on an Azure c600 imaging system. 229
DSP Crosslinking 230
HeLa cells were transfected with VP35-WT or VP35-S129A plasmids as previously indicated. 231
Twenty-four h post-transfection the cells were incubated in a PBS reaction buffer with or without 232
the Dithiobis(succinimidylpropionate) DSP cross-linker (Thermo Scientific) at final concentration 233 of 1 mM for 30 min at RT. The reaction was quenched by the addition of a stop solution (1M 234
Tris-HCl pH 7.5) for 15 min. The cells were subsequently lysed in the modified RIPA buffer and 235 resuspended in a non-reducing sample buffer (Thermo Scientific) and subjected to SDS-PAGE 236 and immunoblot analysis. 237
Molecular cloning, expression and purification of recombinant proteins 238
Constructs encoding for the recombinant EBOV (Zaire ebolavirus, Yambuku-Mayinga, 239
GenBank: NC_002549.1) WT and S129A VP35 oligomerization domains (residues 83-175) 240
were subcloned into pET21b vectors (Novagen) from synthetic DNA preparations (BioCat), then 241 expressed in E.coli BL21 (DE3) cells and purified by affinity and size-exclusion chromatography 242
as previously described (Zinzula et al 2019) . Briefly, heat-shock transformed bacterial cells were 243 grown in LB medium (Carl-Roth) at 37 ºC and 200 rpm up to 0.8 optical density at 600 nm, then 244
induced at 20 ºC with 0.5 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) (Carl-Roth) for 16 245
hours. Proteins were purified by affinity on a 1 mL complete HisTag Purification Column (Roche) 246
and by size-exclusion on a Superose 12 10/300 GL (GE Healthcare) column, respectively. 247
Miniaturized differential scanning fluorimetry (nanoDSF) 248
NanoDSF was performed by using a Prometheus NT. 48 2019a) The structure processing and optimization were carried out by means of Maestro Protein 284
Preparation Wizard default setting (2018) . Original water molecules were removed. After 285 preparation, the structure was refined to optimize the hydrogen bond network using OPLS_2005 286 force field. (Kaminski et al., 2001) . S129A mutation was generated starting from VP35-WT. 287
Therefore, the mutant geometry was optimized with a full minimization protocol considering 288
OPLS_2005 force field (Kaminski et al., 2001) and GB/SA implicit water, setting 10000 steps 289
interactions analysis with Polak-Ribier Coniugate Gradient (PRCG) method and a convergence 290 criterion of 0.1 kcal/(molÅ). 291
Luciferase reporter gene assay for IFN promoter activation 292
The luciferase reporter gene assay for IFN promoter activation was adapted from (Fanunza et  293 al., 2018b). HEK293T cells (1.5 × 10 4 cells/well) were seeded in 96-well plates 24 h before 294 transfection. Cells were transfected using T-Pro P-Fect Transfection Reagent, according to the 295 manufacturer's protocol. Plasmids pGL-IFN-β-luc (60 ng), pRL-TK (10 ng), and various dilutions 296 (100, 10, 1.0, 0.1, 0.01 ng) of pcDNA3 vector control (VC), pcDNA3_VP35-WT, or 297 pcDNA3_VP35-S129A were mixed with the transfection reagent in reduced serum medium 298
Optimem (Gibco) and incubated 20 min at RT. were calculated using GraphPad Prism 6.01 software (GraphPad Software, Inc.; San Diego, 313
CA, USA). 314
RT-PCR assay for ISG expression 315
HEK293T cells (3 × 10 5 cells/well) resuspended Dulbecco's modified Eagle's medium 316
supplemented with 10% fetal bovine serum were seeded in 6-well plates, pre-treated with 500 µl 317
of Poly-D-lysine hydrobromide 100µg/ml for 1 h. After 24 h cells were transfected with 2500 ng 318 of plasmid (pcDNA3 vector control (VC), pcDNA3_VP35-WT, or pcDNA3_VP35-S129A) using 319
Lipofectamine 3000 transfection reagent, as per manufacturer's instruction. Twenty-four h after 320 transfection, cells were stimulated with 2500 ng of IAV-RNA, pre-mixed with the transfection 321 reagent in reduced serum medium Optimem, and incubated for 24 hours at 37 °C in 5% CO 2 . 322
Total RNA was extracted from transfected cells with TRIzol® Reagent (Invitrogen). RNA was 323 then reverse transcribed and amplified using Luna Universal One-Step RT-qPCR kit (New Data were analyzed with Opticon Monitor 3.1. mRNA expression levels were normalized to the 331 level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), with percentage of gene 332 expression over the VC (indicated as 100%). Mean ± standard deviation values of two replicates 333
and paired, two-tailed t tests were calculated using GraphPad Prism 6.01 software. 334
Immunoblot for ISG56 expression 335
HeLa cells (1 × 10 6 cells) were transfected with the indicated plasmids using 2 µL of the 336 transfection reagent Lipofectamine 2000 (Thermo Fisher Scientific) per 1 µg DNA per 337 manufacturer's instructions. Twenty four h post-transfection the cells were mock treated or 338 treated with 10 µg/mL of poly I:C (InvivoGen). Twenty-four h post -treatment cells were 339
harvested, lysed in modified RIPA buffer and subjected to SDS-PAGE and immunoblot as 340 aforementioned with the indicated antibodies. 341
Minigenome Assay 342
A RNA polymerase II-driven EBOV minigenome was used as previously described ( reserved from a representative replicate and subjected to immunoblotting as described below.
352
To account for potential differences in transfection efficiency, firefly luciferase activity was 353 normalized to Renilla luciferase values and plotted as fold activity calculated relative to the no L 354
control. Mean ± standard error of the mean (SEM) values and paired, two-tailed t tests were 355 calculated using GraphPad Prism 7.05 software. 356
Results

357
EBOV VP35 homo-oligomerization domain contains a putative regulatory serine 358 phosphorylation site 359
Given that VP35 is analogous to the phosphoprotein of rhabdoviruses and paramyxoviruses, we 360 first sought to examine EBOV VP35 for sites of phosphorylation by mass spectrometry (MS). 361
Affinity-tagged VP35 was over-expressed in HeLa cells and isolated by immunoaffinity 362 purification. Among predicted phosphorylation sites identified by MS analysis, Ser129 was 363 chosen to evaluate for regulatory phosphorylation function due to its position, which lies just 364 outside the coiled-coil region responsible for VP35 homo-oligomerization ( Figure 1A and C) . 365
Moreover, multiple sequence alignment of all ebolavirus species revealed conservation among 366 all ebolavirus species except BOMV ( Figure 1B) . BOMV is a newly identified ebolavirus species 367 and has not yet been shown to be pathogenic in humans. All other ebolaviruses except RESTV 368 are pathogenic in humans, thus we reasoned the conservation of Ser129 may be functionally 369
important. Accordingly, it was hypothesized that Ser129 plays an important regulatory role for 370
VP35 as a NNSV P protein. 371
VP35-S129A has moderately diminished oligomerization capacity 372
Homo-oligomerization of VP35 is known to be required for both replication and contributes to Ser129 impacts the ability of VP35 to oligomerize. Using a non-phosphorylated mimic of VP35 375 generated by alanine substitution at Ser129 (VP35-S129A), we first evaluated the ability of 376 VP35-S129A to interact with VP35-WT. HeLa cells were transfected with HA-VP35-WT or His-377 VP35-S129A alone and in combination with FLAG-VP35-WT. After 24 h, proteins were 378 extracted and immunoprecipitations (IPs) using anti-FLAG beads were performed. IP samples 379
and whole cell lysates (WCLs) were then subjected to SDS-PAGE and products were analyzed 380 by immunoblot. As expected, HA-VP35-WT was shown to be pulled down only in the presence 381 of FLAG-VP35-WT, demonstrating specificity of binding (Figure 2A, top panels) . Similarly, His-382
VP35-S129A was also pulled down in the presence of FLAG-VP35-WT, indicating that the 383 VP35-S129A mutant retains the ability to self-associate. Appropriate protein expression was 384 confirmed by WCL analysis (Figure 2A, bottom panels) . 385
To next evaluate VP35-S129A oligomerization ability, we performed cross-linking experiments, 386
along with a series of biochemical studies. VP35-WT and VP35-S129A were separately over-387 expressed in HeLa cells for 24 h. Following cross-linking with Dithiobis(succinimidylpropionate) 388
(DSP), the oligomeric forms of VP35 were analyzed by immunoblot under non-reducing, 389
unboiled conditions. After cross-linking with DSP, VP35-WT had a marked increase in higher 390
oligomeric forms, as well as a modest decrease in monomeric form, relative to that of the non-391 DSP treated VP35-WT isolate ( Figure 2B ). Notably though, cross-linking of VP35-S129A 392 resulted in a modest reduction in the formation of higher oligomeric forms compared to VP35-393
WT. This indicates that while decreased, VP35-S129A can still oligomerize. 394 . Given that our VP35-S129A mutant displayed reduced 398 capability to undergo oligomerization under cross-linking experiments, we next wanted to 399 assess if the introduced mutation was affecting the quaternary structure of the oligomerization 400 domain. To this aim, we performed size-exclusion chromatography coupled with multi-angle 401 light scattering (SEC-MALS) on a truncated VP35 construct bordering the N-terminal coiled-coil 402
(residues 75-185). WT and S129A VP35 oligomerization domains both eluted in one distinct 403 peak with an average molecular mass of 51.8 and 51.6 kDa, respectively ( Figure 2C) . 404
Corresponding to roughly 3.9 folds in stoichiometry compared to their monomeric molecular 405
weight, these masses are consistent with the presence of a homo-tetramer in solution for both 406
WT and S129A VP35. We then wondered if the defective oligomerization phenotype observed 407 by the cross-linking immunoblot was due to any difference in stability between the homo-408 tetrameric oligomerization domain of the WT and the S129A mutant. To address this question, 409
we performed thermal stability analysis by miniaturized differential scanning fluorimetry 410 (nanoDSF). As shown by their thermal denaturation curves, WT and S129 VP35 oligomerization 411 domains displayed melting temperature (Tm) values of 72.1°C and 70.6°C, respectively ( Figure  412 2D). Although both these inflection points are reminiscent of a stable tertiary structure, the lower 413
Tm displayed by the S129A mutant suggests that a higher degree of flexibility exists at the level 414 of the VP35 oligomerization domain. 415 Therefore, in order to assess if the S129A mutation could cause structural perturbations 416 sufficient to locally affect the oligomerization domain folding, we tested it by circular dichroism 417 (CD) spectroscopy. In agreement to what has been previously observed for the WT VP35 418 oligomerization domain (Luthra et al., 2015; Zinzula et al., 2019) , the CD spectra of the VP35 419 S129A mutant was typical to that of a protein mainly consisting of -helices. Moreover, the 420 value of the 222/208 nm ellipticity ratio was close to 1 for both proteins at all three temperature 421 values tested (4°C, 23°C and 37°C), indicating that the coiled-coil motif -through which the -422
helices interactremains in place in the S129A mutant. However, the difference in the ellipticity 423
profile of S129A suggests that this mutation introduces some local conformational change 424
( Figure 2E ). Consistent with this hypothesis, deconvolution of CD spectra and analysis of the 425 secondary structure content showed that the VP35 S129A oligomerization domain has a lower 426
-helical percentage with respect to WT at all temperature values tested, and that this content 427 diminishes as temperature increases ( Figure 2F ). This result indicates that a more flexible and 428 relaxed conformation is applied at the level of the VP35 coiled-coil superhelix upon the 429 substitution of Ser-to-Ala at residue 129. 430
We further investigated the effect of S129A on VP35 oligomerization domain conformation by 431 computational modeling. Starting from the available WT crystal structure, a Ser-to-Ala 432 substitution was made and the oligomerization domain was subjected to energy minimization. 433
The resulting structure was then compared to WT ( Figure 3A and B) . Conformation was 434 unaffected but did cause a loss of hydrogen bonds between Ser129 and the neighboring Ala125 435
( Figure 3C) . The implicated biological effect may contribute to protein-protein interaction or 436 modulatory phosphorylation ( Figure 3D ). Taken together, these data indicate that VP35-S129A 437 has reduced capacity to oligomerize relative to VP35-WT and suggests a biological effect. 438
VP35-S129A retains IFN antagonist function 439
To assess a role of Ser129 in VP35 function, we examined IFN antagonist function, including 440 VP35 inhibition impact on the RIG-I-mediated signaling cascade and subsequent impairment of 441 the interferon stimulated-gene (ISG) expression. Using a luciferase reporter gene assay, we first 442 evaluated VP35-WT and VP35-S129A inhibition of dsRNA-induced RIG-I activation of the IFN-β 443
promoter. HEK 293T cells were co-transfected with pGL-IFN-β-luc, pRL-TK, and various 444 dilutions of a vector control, VP35-WT, or VP35-S129A. Twenty-four h post-transfection, cells 445
were stimulated with influenza A virus (IAV)-RNA. After 24 h, reporter activity was measured to 446 assess IFN inhibition. IFN-β promoter activation was significantly inhibited by both VP35-WT 447 and VP35-S129A at comparable efficiencies ( Figure 4A ). Next, we tested the effect of VP35-WT 448 and VP35-S129A on expression of ISGs upon stimulation by viral RNA or poly I:C. Using RT-449 qPCR, we analyzed gene expression of two well characterized ISGs, ISG15 and 2'-5'-450 oligoadenylate synthetase (OAS 2'-5'). Expression of these ISGs induced by stimulation with 451
vRNA was significantly reduced by the presence of either VP35-WT or VP35-S129A, relative to 452 the vector control. Specifically, ISG15 expression was inhibited 87% by VP35-WT and 90% by 453 VP35-S129A, and OAS 2'-5' expression was inhibited 87% by VP35-WT and 95% by VP35-454 S129A ( Figure 4B) . Further, the effect of poly I:C stimulation on ISG56 protein expression was 455 assessed by immunoblot. HeLa cells were transfected with vector control, VP35-WT, or VP35-456 S129A. Twenty-four h post-transfection cells were left unstimulated or stimulated with poly I:C. 457
Both VP35-WT and VP35-S129A were able to inhibit ISG56 protein expression, with levels 458 comparable to that of the non-stimulated vector control ( Figure 4C ). Collectively, the data show 459 that VP35-S129A retains IFN antagonist activity, indicating that VP35 Ser129 does not impact 460 IFN antagonist function. 461 VP35-S129A abrogates EBOV minigenome activity and interaction with L 1-505 462
Since VP35 is an essential polymerase cofactor, we next evaluated the effect of VP35-S129A 463 on EBOV minigenome activity. Plasmids encoding EBOV minigenome assay components NP, 464 L, VP35, VP30 and the 3E5E-luciferase minigenome, along with Renilla luciferase to control for 465 transfection efficiency variability, were co-transfected in HeLa cells. Forty-eight h post-466 transfection, a dual-luciferase assay was used to measure reporter activity. Notably, the 467 presence of VP35-S129A nearly abolished minigenome activity relative to VP35-WT, with 468
activity level close to that of the no L control ( Figure 5A ). Additionally, representative lysates 469 from the minigenome assay were subjected to immunoblotting to confirm appropriate 470 expression of the WT and mutant ( Figure 5B ). While both VP35-WT and VP35-S129A 471
predominantly expressed one major species of the same migration (~38 kD), other bands were 472
observed. Specifically, VP35-WT contained modest upper bands at ~45 kD and ~85 kD), 473
whereas VP35-S129A contained a modest lower band at ~35 kD. This may be representative of 474
differential PTMs between VP35-WT and VP35-S129A, such as differing phosphorylation 475
states. Overall, these data suggest that Ser129 impacts VP35 transcription and replication 476 function. 477
To further investigate the role of Ser129 on VP35 replication function, we next examined 478
whether VP35-S129A retains the ability to interact with NP and L by co-IP experiments. HeLa 479 cells were transfected with FLAG-VP35-WT or HIS-VP35-S129A in the absence or presence of 480 either HA-NP or HA-L 1-505 . The previously described HA-L 1-505 truncation mutant includes the 481 VP35 interaction site and was used due to protein detection issues of full length L (Shabman et  482 al., 2013, Trunschke et al., 2013) . Vector control was included in transfections with VP35-WT or 483 VP35-S129A alone to keep total DNA amounts constant. After 24 h, proteins were harvested 484 and applied to IP using HA-tagged beads. After IP, WCLs and IP samples were subjected to 485 SDS-PAGE and products were analyzed by immunoblot. Both VP35-WT and VP35-S129A were 486 pulled down only in the presence of HA-NP, demonstrating specificity of interaction and 487
indicating that VP35-S129A retains the ability to interact with NP ( Figure 5C ). Notably, VP35-488
WT was pulled down with HA-L 1-505 whereas VP35-S129A was not, indicating that the 489 substitution of Ser129 to Ala results in the loss VP35-L interaction ( Figure 5D ). Collectively, 490
these data show that Ser-to-Ala substitution at residue 129 of VP35 abolishes minigenome 491 activity through loss of interaction between VP35-S129A and L but does not affect IFN 492
antagonist function, effectively uncoupling IFN antagonist and replication functions. This is the 493 first report to suggest phosphorylation contributes a regulatory role in VP35 function and 494 presents a potential therapeutic target. 495
Discussion 496
The most highly phosphorylated protein of NNSVs is generally the P protein, with 497 phosphorylation universally regarded as important to P protein function. indicate that the S129A mutant possesses a higher degree of flexibility at the level of the VP35 512 oligomerization domain, with secondary structure content analysis indicating that a more flexible 513
and relaxed conformation is applied at the level of the VP35 coiled-coil superhelix. We further 514
show that while interactions with VP35-WT and NP remain intact, VP35-S129A exhibits 515
impaired ability to interact with the viral polymerase. . It has been shown that 523 VSV P protein must undergo phosphorylation-dependent homo-oligomerization to become 524 transcriptionally active (Gao and Lenard, 1995) . Consistent with these findings are the nanoDSF 525 results in this study which indicate that the VP35-S129A mutant possesses a higher degree of 526 flexibility at the level of the VP35 oligomerization domain, and severely decreases EBOV 527 minigenome activity. In addition, the oligomerization domain of MuV and hPIV3 P proteins has 528 been shown to have an enhancing effect on the P-L interaction, which further supports the 529 findings here (Choudhary et al., 2002 , Pickar et al., 2015 . 530 VP35 has been shown to be phosphorylated by IKKε and TBK-1 in vitro, which suggests the 531 possibility that its function may be modulated by these kinases (Prins et al., 2009) . In this case 532 VP35 exerts IFN-antagonist function by preventing TBK-1 and/or IKKε from activating 533 IRF3/IRF7. It has yet to be determined whether VP35 becomes phosphorylated in EBOV-534 infected cells, though, and whether that modulates its function. The extent to which VP35 is 535 phosphorylated by these kinases in EBOV-infected cells would be influenced by the extent to 536 which VP35 acts as a decoy substrate for IKKε and TBK-1 relative to the extent VP35 merely 537 prevents kinase activation via steric inhibition (Prins et al., 2009 ). Even so, in our study here the 538 VP35-S129A mutant impaired replication function but did not affect VP35 IFN antagonist 539 function. Given the high virulence of EBOV infection and the multifunctional nature of VP35, it 540 seems unlikely that VP35 phosphorylation by IKKε and TBK-1 would detrimentally affect virus 541 replication. Considering then that the IFN antagonism of the VP35-S129A mutant remained 542 intact instead suggests that another host kinase(s) would be involved in the potential 543 phosphorylation of Ser129. 544
Previous studies have demonstrated phosphorylation of NP and VP30; moreover, a functional 545 significance for VP30 phosphorylation has been described (Elliott et al., 1985 demonstrating that VP35-S129A retains the capacity to oligomerize at levels near that of WT. 886
HeLa cells were transfected with VP35-WT or VP35-S129A. Twenty-four h after transfection, 887 cells were left untreated or treated with 1 mM of DSP. Asterisks denote oligomeric forms. (C) 888
Quaternary structure analysis of EBOV VP35-WT oligomerization domain compared to S129A 889 mutant by SEC-MALS. Absorbance peaks (280 nm) of protein ertention volumes and absolute 890 molecular masses under the main peak of each sample are indicated by continuous and dashed 891 lines, respectively. (D) Thermal stability analysis of EBOV VP35-WT and S129A oligomerization 892 domain by nanoDSF. Variation in the protein intrinsic 330/350 nm fluorescence ratio upon 893 thermal denaturation and the corresponding first derivative curves are indicated by continuous 894 and dashed lines, respectively. Tm values are defined by the first derivative curve peak of each 895 sample. (E) Far-UV CD spectra of EBOV VP35-WT and S129A oligomerization domain at 896 different temperature values. The 222/208 nm MRE ratio value indicating the coiled-coil folding 897 of each sample is annotated. (F) Secondary structure content analysis of EBOV VP35-WT and 898 S129A oligomerization domain by CD spectra deconvolution with the CONTINLL method. 899
Structure composition of -helices are indicated as percentages of the entire amino acid 900 sequence. 901 presence of vector control (VC), VP35-WT (WT) or VP35-Ser129Ala (S129A). HEK293T cells 907
were co-transfected with 60 ng of pGL-IFN-β-luc, 10 ng pRL-TK, and decreasing amounts (100, 908
10, 1.0, 0.1, 0.01 ng) of VC, WT, or S129A plasmid. Twenty-four h after transfection, cells were 909 additionally transfected with IAV-RNA. After 24 h cells were lysed and luciferase activity was 910 measured. (B) RT-qPCR assay of interferon-stimulated gene (ISG) expression upon IAV-RNA 911 stimulation in the presence of VC, WT, or S129A plasmids. HEK293T were transfected with 912 2500 ng of VC, WT, or S129A plasmid. Twenty-four h after transfection, cells were stimulated 913 with 2500 ng of IAV-RNA. After 24 h, total RNA was extracted, reverse transcribed, and 914 subjected to quantitative real-time PCR (RT-qPCR) for the analysis of ISG15 and 2'-5'-915 oligoadenylate synthetase (OAS 2'-5') levels. mRNA expression levels were normalized to the 916 level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data represent mean ± SD 917 (n=3) of two independent experiments. (C) Effect of VP35-WT and VP35-S129A on ISG56 918 expression upon poly I:C stimulation. HeLa cells were left untransfected or transfected with 919 VP35-WT or VP35-S129A. Twenty-four h after transfection, cells were left untreated or treated 920 with 10 µg/mL of poly I:C. After 24 h, cells were harvested and subjected to immunoblotting. 921
Data represent mean ± SD. *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, **** ≤ 0.0001. 922 Figure 5 . VP35-S129A abrogates EBOV minigenome activity and interaction with L 1-505. A) 923
Effect of VP35-WT and VP35-S129A on minigenome activity. HeLa cells were transfected with 924 minigenome components (125 ng pCAGGS-HA-NP, 125 ng pCAGGS-FLAG-VP35, 50 ng 925 pCAGGS-V5-VP30, 50 ng pRL-TK, 500 ng pCAGGS-L, and 750 ng of pCAGGS-3E5E-926 luciferase). Forty-eight h post-transfection, reporter activity was measured. Data represent 927 mean ± SEM from one representative experiment (n=3) of at least three independent 928 experiments (B) Immunoblot confirmation of VP35-WT and VP35-S129A protein levels in the 929 minigenome (C) CoIP experiment demonstrating that VP35-S129A retains the ability to interact 930 with NP. (D) Representative IF images of FLAG-VP35-WT or HIS-VP35-S129A in the presence 931 of HA-NP. (E) CoIP experiment demonstrating a lost interaction between VP35-S129A and L 1-932 505 . IPs in (C and E) were performed with anti-HA beads. FLAG-VP35-WT or HIS-VP35-S129A 933 (red), HA-NP or HA-L 1-505 , Hoechst 33342 nuclear stain (blue) were visualized by confocal 
